Organon
Update in progressOGN (NYSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - General
Organon & Co. develops women’s health therapies and medical devices for prescription use worldwide, including the United States, Europe, Canada, and beyond. Its women’s health portfolio covers contraception and fertility brands such as Nexplanon, NuvaRing, and daily pills, plus fertility drugs like Follistim and Elonva. It also offers biosimilars and medicines for cholesterol, hypertension, asthma, dermatology, bone health, and more. Based in Jersey City, NJ.
Company score
- Sentiment
- 0.39
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.02
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.51
- Governance
- -0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE (NYQ)
- LocationUnited States
- Founded1923
- Employees10,000
- Websitewww.organon.com
Identifiers
- ISINUS68622V1061
- FIGIBBG00ZQRGW24
- CUSIP68622V106
- CIK0001821825